These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic. Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356 [TBL] [Abstract][Full Text] [Related]
16. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Leist TP; Vermersch P Curr Med Res Opin; 2007 Nov; 23(11):2667-76. PubMed ID: 17880754 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. Hettle R; Harty G; Wong SL J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273 [TBL] [Abstract][Full Text] [Related]
18. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study. Brownlee W; Amin A; Ashton L; Herbert A Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis]. Avxentyev NA; Davydovskaya MV; Makarova YV; Frolov MY; Klabukova DL Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(8):30-36. PubMed ID: 34481433 [TBL] [Abstract][Full Text] [Related]
20. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Leist T; Cook S; Comi G; Montalban X; Giovannoni G; Nolting A; Damian D; Syed S; Galazka A Mult Scler Relat Disord; 2020 Nov; 46():102572. PubMed ID: 33296971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]